News & Events about Collegium Pharmaceutical Inc.
Globe Newswire
9 months ago
Highlights 2022 environmental, social and governance achievementsSTOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and ...
Globe Newswire
9 months ago
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers ...
Globe Newswire
11 months ago
Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million $100 Million Share Repurchase Program Authorized by the ...
Globe Newswire
11 months ago
Mike Heffernan appointed Chairman of NMD Pharmas Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen several successful IPOs and trade sales Aarhus, Denmark, 3 January 2023 NMD Pharma A/S, a ...
Globe Newswire
11 months ago
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expirySTOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of ...